-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-
-Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study
expected in Q4:21-
-Ebopiprant: Global License Agreement completed with Organon -
-Actively pursuing new indications and partnerships to maximize value of pipeline candidates-
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – August 5, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the quarter ended June 30, 2021 and provided a business update.
“The outset of 2021 was focused on strengthening the financial position of the company, and we have continued to execute on our strategic plan, which most recently includes the global license to Organon of development, manufacturing and commercial rights to ebopiprant,” said Brian O’Callaghan, CEO of ObsEva. “This partnership is an important validation of ObsEva’s ability to generate value, and we view Organon as the ideal partner for the development and commercialization of ebopiprant to address the significant unmet need in preterm labor. In parallel, we remain laser focused on advancing linzagolix through the regulatory approval process and preparing for its commercialization. We look forward to providing additional updates in the near future.”
Anticipated Milestones
ObsEva expects to achieve the following key clinical and regulatory objectives in 2021:
- Linzagolix for uterine fibroids: U.S. New Drug Application (NDA) submission (Q3:21); Committee for Medicinal Products for Human Use (CHMP) marketing approval recommendation (Q4:21)
- Linzagolix for endometriosis: Phase 3 EDELWEISS 3 topline results readout (Q4:21)
Pipeline Update
- Linzagolix for Uterine Fibroids: ObsEva is developing linzagolix, an oral GnRH receptor antagonist with the potential to treat more women due to its potential best-in-class efficacy, a favorable tolerability profile and unique, and flexible dosing options for the treatment of uterine fibroids. If approved, linzagolix will be the only GnRH antagonist in uterine fibroids with a low dose non-ABT option to address the needs of women who cannot or do not want to take hormones. The Company is working closely with the European Medicines Agency (EMA) to achieve marketing approval, with an approval recommendation (positive opinion) from the CHMP projected in Q4:2021. The Company is also working to submit an NDA, projected in Q3:2021.
- Linzagolix for Endometriosis: The EDELWEISS 3 study in the EU is progressing as planned, with randomization of patients completed and primary endpoint data expected in Q4:2021. The ongoing Phase 3 EDELWEISS 3 study (Europe and US) enrolled 486 patients with endometriosis-associated pain, with a co-primary endpoint of response on both dysmenorrhea (menstrual pain) and non-menstrual pelvic pain. The study includes a 75 mg once-daily dose without hormonal ABT, and a 200 mg once-daily dose in combination with hormonal ABT (1 mg E2 / 0.5mg NETA). Subjects who complete the initial six-month treatment period have the option to enter a six-month treatment extension.
- Ebopiprant for Treatment of Preterm Labor: ObsEva recently granted a license to Organon (NYSE:OGN) for the global development, manufacturing and commercial rights to ebopiprant. Plans for the future development of ebopiprant are yet to be announced.
- Nolasiban for In Vitro Fertilization: ObsEva is also advancing nolasiban, an oral oxytocin receptor antagonist, to improve live birth rates in women undergoing in vitro fertilization.
Financial Update
Net loss for the quarter ended June 30, 2021 was $19.1 million, or $0.25 per share, compared with a net loss of $18.2 million, or $0.38 per share, for the quarter ended June 30, 2020. Research and development expenses were $14.5 million and general and administrative expenses were $3.9 million for the quarter ended June 30, 2021, compared with $15.4 million and $2.2 million, respectively, for the corresponding prior year quarter. Net loss for the quarter ended June 30, 2021 included non-cash expenses of $0.9 million for stock-based compensation, compared with $1.4 million for stock-based compensation in the corresponding prior year quarter.
As of June 30, 2021, ObsEva had cash and cash equivalents of $58.9 million, compared with $31.2 million as of December 31, 2020.
The second quarter 2021 financial report will be available in the financial reports section of the Company’s website.
To access the financial reports section of the Company’s website, please click [here].
To access the second quarter 2021 financial report directly, please click [here].
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and other similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva’s product candidates, ObsEva’s ability to generate value, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602
Consolidated Statements of Comprehensive Loss
| Three-Month Period Ended June 30, | Six-Month Period Ended June 30, | |||||||||||||||
| (in USD ’000, except share and per share data) - unaudited | 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Operating income other than revenue | 4 | 4 | 10 | 8 | ||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| Research and development expenses | (14,485 | ) | (15,377 | ) | (30,001 | ) | (32,565 | ) | ||||||||
| General and administrative expenses | (3,888 | ) | (2,191 | ) | (8,079 | ) | (5,900 | ) | ||||||||
| Total operating expenses | (18,373 | ) | (17,568 | ) | (38,080 | ) | (38,465 | ) | ||||||||
| OPERATING LOSS | (18,369 | ) | (17,564 | ) | (38,070 | ) | (38,457 | ) | ||||||||
| Finance income | (55 | ) | 48 | 574 | 108 | |||||||||||
| Finance expense | (690 | ) | (690 | ) | (1,601 | ) | (1,701 | ) | ||||||||
| NET LOSS BEFORE TAX | (19,114 | ) | (18,206 | ) | (39,097 | ) | (40,050 | ) | ||||||||
| Income tax (expense) / benefit | (30 | ) | 38 | (51 | ) | 19 | ||||||||||
| NET LOSS FOR THE PERIOD | (19,144 | ) | (18,168 | ) | (39,148 | ) | (40,031 | ) | ||||||||
| Net loss per share | ||||||||||||||||
| Basic | (0.25 | ) | (0.38 | ) | (0.54 | ) | (0.86 | ) | ||||||||
| Diluted | (0.25 | ) | (0.38 | ) | (0.54 | ) | (0.86 | ) | ||||||||
| Weighted Average Number of Shares Outstanding | 75,809,484 | 47,709,508 | 72,211,911 | 46,717,535 | ||||||||||||
Consolidated Balance Sheets
| (in USD ’000) - unaudited | June 30, 2021 | December 31, 2020 | ||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | 58,923 | 31,183 | ||||||
| Other receivables | 458 | 397 | ||||||
| Prepaid expenses | 8,010 | 5,388 | ||||||
| Total current assets | 67,391 | 36,968 | ||||||
| Non-current assets | ||||||||
| Right-of-use assets | 834 | 1,425 | ||||||
| Furniture, fixtures and equipment | 65 | 151 | ||||||
| Intangible assets | 26,608 | 26,608 | ||||||
| Other long-term assets | 284 | 295 | ||||||
| Total non-current assets | 27,791 | 28,479 | ||||||
| Total assets | 95,182 | 65,447 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Other payables and current liabilities | 7,515 | 10,760 | ||||||
| Accrued expenses | 10,312 | 10,248 | ||||||
| Current lease liabilities | 694 | 696 | ||||||
| Total current liabilities | 18,521 | 21,704 | ||||||
| Non-current liabilities | ||||||||
| Non-current lease liabilities | 567 | 952 | ||||||
| Non-current borrowings | 25,519 | 25,300 | ||||||
| Post-employment obligations | 8,074 | 8,218 | ||||||
| Other long-term liabilities | 877 | 919 | ||||||
| Total non-current liabilities | 35,037 | 35,389 | ||||||
| Shareholders’ equity | ||||||||
| Share capital | 6,948 | 4,878 | ||||||
| Treasury shares | (630 | ) | (304 | ) | ||||
| Share premium | 424,567 | 356,822 | ||||||
| Reserves | 29,282 | 26,353 | ||||||
| Accumulated losses | (418,543 | ) | (379,395 | ) | ||||
| Total shareholders’ equity | 41,624 | 8,354 | ||||||
| Total liabilities and shareholders’ equity | 95,182 | 65,447 | ||||||
###
Attachment
